NCT04841538 2022-04-29
A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors
Elpiscience Biopharma, Ltd.
Phase 1/2 Withdrawn
Elpiscience Biopharma, Ltd.
Health Pharma Professional Research
Eli Lilly and Company